^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IGM-2644

    i
    Other names: IGM-2644, CD38 x CD3 based IgM bispecific antibody
    Associations

    News

    Trials
    Company:
    IGM Biosciences
    Drug class:
    CD3 agonist, CD38 inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=100, Recruiting, IGM Biosciences, Inc.
    New P1 trial
    |
    IGM-2644
    12ms
    HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING (EHA 2023)
    Our preclinical data indicate that IGM-2644 maintains activity in the presence ofdaratumumab. A Phase 1 clinical trial in r/r MM is being planned to evaluate the safety and pharmacokinetics of IGM-2644. The clinical study will evaluate these preclinical findings, including the treatment of patients with circulating serum levels of daratumumab.
    IO biomarker
    |
    CD38 expression
    |
    Darzalex (daratumumab) • IGM-2644